Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.

• Why it matters: Patients with relapsed/refractory multiple myeloma have limited treatment options after multiple prior therapies, highlighting the need for effective new treatments.
• What they did: A phase 1 trial enrolled 84 adults with a median of five prior regimens, administering a GPRC5D-targeted CAR T-cell therapy across doses of 25 to 450 million cells, assessing safety and efficacy.
• The result: The therapy demonstrated a manageable safety profile, with most adverse events being transient and low-grade, and showed promising progression-free and overall survival, supporting further research.